Accueil > Actualité
Actualite financiere : Actualite bourse

Ipsen: presents phase III NAPOLI 3 trial

( - At ASCO GI Ipsen presented the NAPOLI 3 phase III trial of the Onivyde regimen, which showed positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma.

The investigational Onivyde treatment (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile.

Ipsen said that these results represent a potential breakthrough in an aggressive and difficult-to-treat cancer.

Copyright (c) 2023 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.